3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
6
Esophageal Neoplasms
4
Gastrointestinal Neoplasms
3
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Adenocarcinoma
2
Solid Tumor
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Neoplasms, Unknown Primary
1
Nasopharyngeal Carcinoma
1
Locally Advanced Gastric Adenocarcinoma
1
Hand-Foot Syndrome
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Biliary Tract Neoplasms
1
Bile Duct Neoplasms
1
Adenocarcinoma Of Esophagus
1
Interventions
Gemcitabine
24
Cisplatin
14
Capecitabine
12
Oxaliplatin
11
Fluorouracil
11
Leucovorin
7
Irinotecan
7
Radiotherapy
5
durvalumab
4
Photochemotherapy
3
Magnetic Resonance Spectroscopy
3
Long-Term Synaptic Depression
3
Erlotinib Hydrochloride
3
Cholangiopancreatography, Endoscopic Retrograde
3
Carboplatin
3
trifluridine tipiracil drug combination
2
regorafenib
2
olaparib
2
ceralasertib
2
Stents
2
Sorafenib
2
Radiosurgery
2
Radiofrequency Ablation
2
Liver Transplantation
2
Filgrastim
2
Dihematoporphyrin Ether
2
1-phenyl-3,3-dimethyltriazene
2
zimberelimab
1
tivozanib
1
titanium silicide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Bile Duct Neoplasms
×
tegafur-gimeracil-oteracil
×
Clear all
NCT01845337
2023-05-12
TOFFEE
University of Edinburgh
Phase 2
Completed
59 enrolled